Dynamic Changes on the Battlefield: Giants Accelerate ‘Buy Buy Buy’

Competition in the GLP-1 market is evolving into a multidimensional war involving technology, cost control, and business models. After the chaos of the post-Chinese New Year, the global metabolic disease drug R&D field is abuzz. Pfizer China and Hangzhou First Reach Biotechnology jointly announced a strategic partnership where Pfizer acquired exclusive commercial rights to Enocholipide injection in mainland China for a maximum total of $4.95 billion. In a different move, Danish giant Novo Nordisk announced a $21 billion deal with US biotech company Vivtex to develop next-generation oral drugs for obesity and diabetes. These back-to-back high-value deals signal a fundamental…